<p>根据最近向证券交易委员会提交的文件，维吉尼亚退休系统（VIRGINIA RETIREMENT SYSTEMS ET Al）在 2023 年第四季度将其在 BridgeBio Pharma, Inc.（NASDAQ:BBIO - 免费报告）的股份增加了 146.2%。该基金在季度内购买了额外的 15,350 股后，持有该公司 25,850 股股票。在最近的报告期结束时，维吉尼亚退休系统在 BridgeBio Pharma 的持股价值为 1,977,000 美元。</p>
<p>获取 <strong>BridgeBio Pharma</strong> 的提醒：</p>
<ul>
<li>BridgeBio 动荡的一周让生物技术股票受到关注</li>
</ul>
<p>其他对冲基金和机构投资者最近也调整了对该公司的持股。Farther Finance Advisors LLC 在第四季度将其在 BridgeBio Pharma 的股份增加了 91.4%。Farther Finance Advisors LLC 现在拥有 513 股该公司的股票，价值 39,000 美元，此前在上个季度购买了额外的 245 股。Aster Capital Management DIFC Ltd 在第三季度获得了 BridgeBio Pharma 的新股份，价值约 31,000 美元。Harvest Fund Management Co. Ltd 在第三季度获得了 BridgeBio Pharma 的新股份，价值约 34,000 美元。First Horizon Corp 在第三季度获得了 BridgeBio Pharma 的新股份，价值约 36,000 美元。最后，亨廷顿国家银行在第三季度将其在 BridgeBio Pharma 的持股增加了 111.7%。亨廷顿国家银行现在拥有 743 股该公司的股票，价值 39,000 美元，此前在该期间购买了额外的 392 股。目前 99.85% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>几位分析师最近对该公司进行了评论。Truist Financial 将 BridgeBio Pharma 的目标股价从 95.00 美元上调至 102.00 美元，并在 4 月 29 日的报告中给予该公司 “买入” 评级。William Blair 在 3 月 10 日的报告中开始覆盖 BridgeBio Pharma，并为该公司设定了 “跑赢大盘” 的评级。加拿大皇家银行在 4 月 9 日的报告中开始覆盖 BridgeBio Pharma，并为该公司设定了 “跑赢大盘” 的评级和 100.00 美元的目标股价。富国银行在 2 月 13 日的报告中将 BridgeBio Pharma 的目标股价从 88.00 美元上调至 98.00 美元，并给予该股票 “超配” 评级。最后，HC Wainwright 在 5 月 11 日的报告中将 BridgeBio Pharma 的目标股价从 100.00 美元上调至 110.00 美元，并给予该股票 “买入” 评级。24 位研究分析师对该股票给予了买入评级，1 位分析师给予了卖出评级。根据 MarketBeat 的数据，BridgeBio Pharma 的平均评级为 “适度买入”，共识目标价为 88.19 美元。</p>
<p><strong>查看我们对 BridgeBio Pharma 的最新股票分析</strong></p>
<h2>BridgeBio Pharma 股票表现</h2>
<p>BridgeBio Pharma 的股票在周五开盘价为 66.13 美元。该股票的 50 日移动平均线为 71.38 美元，200 日移动平均线为 71.73 美元。该公司的市值为 129.5 亿美元，市盈率为-17.68，贝塔值为 1.02。BridgeBio Pharma, Inc.的 52 周低点为 31.77 美元，52 周高点为 84.94 美元。</p>
<p>BridgeBio Pharma（NASDAQ:BBIO - 获取免费报告）最后一次公布财报是在 5 月 7 日，报告显示该季度每股收益（EPS）为-0.84 美元，低于分析师共识预期的-0.70 美元，差距为 0.14 美元。该季度的收入为 1.9452 亿美元，而分析师预期为 1.7807 亿美元。与去年同期相比，该公司的收入增长了 66.8%。在去年同期，该公司每股收益为-0.88 美元。分析师平均预测 BridgeBio Pharma, Inc.在当前财年将发布-2.27 的每股收益。</p>
<h2>BridgeBio Pharma 的内部买卖</h2>
<p>在其他消息中，董事 Randal W. Scott 在 2 月 17 日的交易中出售了 10,000 股 BridgeBio Pharma 的股票。该股票以平均 75.46 美元的价格出售，总价值为 754,600.00 美元。出售完成后，该董事持有 11,589 股该公司的股票，价值 874,505.94 美元。此次交易使其持股减少了 46.32%。该出售在向证券交易委员会提交的文件中披露，相关文件可在 SEC 网站上获取。此外，首席执行官 Neil Kumar 在 5 月 7 日的交易中出售了 40,000 股 BridgeBio Pharma 的股票。该股票以平均 67.90 美元的价格出售，总价值为 2,716,000.00 美元。出售完成后，首席执行官直接持有 575,686 股该公司的股票，价值约 39,089,079.40 美元。这代表其持股减少了 6.50%。该出售的披露信息可在 SEC 文件中找到。此次交易是在预先安排的 10b5-1 交易计划下执行的。在过去的 90 天内，内部人士已出售 239,084 股公司股票，价值 16,615,979 美元。当前 14.23% 的股票由内部人士持有。</p>
<h2>BridgeBio Pharma 公司简介</h2>
<p>（免费报告）</p>
<p>BridgeBio Pharma, Inc 是一家临床阶段的生物制药公司，总部位于加利福尼亚州帕洛阿尔托。该公司由 Neil Kumar 于 2015 年创立，致力于为患有遗传疾病和癌症的患者发现、开发和提供变革性药物。BridgeBio 采用一个综合模型，涵盖靶点识别、临床前研究、临床开发和商业化，旨在简化从实验室到临床的过程。</p>
<p>BridgeBio 的产品线包括多种治疗方式，包括小分子、生物制剂和基因疗法。</p>
<h2>特色故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 BridgeBio Pharma</li>
<li>MarketBeat 周报 – 05/11 - 05/15</li>
<li>Viking 股价创历史新高——基本面信号显示未来还有更多</li>
<li>Datavalut 获得关注：现在卖出的五个理由</li>
<li>TMC 股票：为什么这家尚未盈利的矿业公司值得关注</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkJJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkJJTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 BridgeBio Pharma 吗？</h2>
<p>在考虑 BridgeBio Pharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 BridgeBio Pharma 并不在名单上。</p>
<p>虽然 BridgeBio Pharma 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BBIO

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

<p>维吉尼亚退休系统等在第四季度将其在 BridgeBio Pharma, Inc.的持股增加了 146.2%，目前持有 25,850 股，价值 1,977,000 美元。其他机构投资者也增加了他们的持股。分析师对该股票的共识评级为 “适度买入”，目标价格为 88.19 美元。BridgeBio 报告的收入为 1.9452 亿美元，但未能达到每股收益预期。内部人士的卖出包括董事 Randal W. Scott 出售的 10,000 股和首席执行官 Neil Kumar 出售的 40,000 股</p>

<p>VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 146.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,850 shares of the company's stock after purchasing an additional 15,350 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al's holdings in BridgeBio Pharma were worth $1,977,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据最近向证券交易委员会提交的文件，维吉尼亚退休系统（VIRGINIA RETIREMENT SYSTEMS ET Al）在 2023 年第四季度将其在 BridgeBio Pharma, Inc.（NASDAQ:BBIO - 免费报告）的股份增加了 146.2%。该基金在季度内购买了额外的 15,350 股后，持有该公司 25,850 股股票。在最近的报告期结束时，维吉尼亚退休系统在 BridgeBio Pharma 的持股价值为 1,977,000 美元。</p>
</div><p>Get <strong>BridgeBio Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>BridgeBio Pharma</strong> 的提醒：</p>
</div><ul>
<li>BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope</li>
</ul>
<div class="lb-trans"><ul>
<li>BridgeBio 动荡的一周让生物技术股票受到关注</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC grew its stake in shares of BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company's stock valued at $39,000 after purchasing an additional 245 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at approximately $31,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at approximately $34,000. First Horizon Corp acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at approximately $36,000. Finally, Huntington National Bank lifted its holdings in shares of BridgeBio Pharma by 111.7% in the 3rd quarter. Huntington National Bank now owns 743 shares of the company's stock valued at $39,000 after buying an additional 392 shares during the period. 99.85% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也调整了对该公司的持股。Farther Finance Advisors LLC 在第四季度将其在 BridgeBio Pharma 的股份增加了 91.4%。Farther Finance Advisors LLC 现在拥有 513 股该公司的股票，价值 39,000 美元，此前在上个季度购买了额外的 245 股。Aster Capital Management DIFC Ltd 在第三季度获得了 BridgeBio Pharma 的新股份，价值约 31,000 美元。Harvest Fund Management Co. Ltd 在第三季度获得了 BridgeBio Pharma 的新股份，价值约 34,000 美元。First Horizon Corp 在第三季度获得了 BridgeBio Pharma 的新股份，价值约 36,000 美元。最后，亨廷顿国家银行在第三季度将其在 BridgeBio Pharma 的持股增加了 111.7%。亨廷顿国家银行现在拥有 743 股该公司的股票，价值 39,000 美元，此前在该期间购买了额外的 392 股。目前 99.85% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several analysts have recently commented on the company. Truist Financial raised their price target on BridgeBio Pharma from $95.00 to $102.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, April 29th. William Blair initiated coverage on BridgeBio Pharma in a report on Tuesday, March 10th. They set an &#34;outperform&#34; rating for the company. Royal Bank Of Canada initiated coverage on BridgeBio Pharma in a report on Thursday, April 9th. They set an &#34;outperform&#34; rating and a $100.00 price objective for the company. Wells Fargo &amp; Company lifted their price objective on BridgeBio Pharma from $88.00 to $98.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, February 13th. Finally, HC Wainwright lifted their price objective on BridgeBio Pharma from $100.00 to $110.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, May 11th. Twenty-four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, BridgeBio Pharma has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $88.19.</p>
<div class="lb-trans"><p>几位分析师最近对该公司进行了评论。Truist Financial 将 BridgeBio Pharma 的目标股价从 95.00 美元上调至 102.00 美元，并在 4 月 29 日的报告中给予该公司 “买入” 评级。William Blair 在 3 月 10 日的报告中开始覆盖 BridgeBio Pharma，并为该公司设定了 “跑赢大盘” 的评级。加拿大皇家银行在 4 月 9 日的报告中开始覆盖 BridgeBio Pharma，并为该公司设定了 “跑赢大盘” 的评级和 100.00 美元的目标股价。富国银行在 2 月 13 日的报告中将 BridgeBio Pharma 的目标股价从 88.00 美元上调至 98.00 美元，并给予该股票 “超配” 评级。最后，HC Wainwright 在 5 月 11 日的报告中将 BridgeBio Pharma 的目标股价从 100.00 美元上调至 110.00 美元，并给予该股票 “买入” 评级。24 位研究分析师对该股票给予了买入评级，1 位分析师给予了卖出评级。根据 MarketBeat 的数据，BridgeBio Pharma 的平均评级为 “适度买入”，共识目标价为 88.19 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on BridgeBio Pharma</strong></p>
<div class="lb-trans"><p><strong>查看我们对 BridgeBio Pharma 的最新股票分析</strong></p>
</div><h2>BridgeBio Pharma Stock Performance</h2>
<div class="lb-trans"><h2>BridgeBio Pharma 股票表现</h2>
</div><p>BridgeBio Pharma stock opened at $66.13 on Friday. The stock has a fifty day moving average of $71.38 and a two-hundred day moving average of $71.73. The company has a market capitalization of $12.95 billion, a price-to-earnings ratio of -17.68 and a beta of 1.02. BridgeBio Pharma, Inc. has a fifty-two week low of $31.77 and a fifty-two week high of $84.94.</p>
<div class="lb-trans"><p>BridgeBio Pharma 的股票在周五开盘价为 66.13 美元。该股票的 50 日移动平均线为 71.38 美元，200 日移动平均线为 71.73 美元。该公司的市值为 129.5 亿美元，市盈率为-17.68，贝塔值为 1.02。BridgeBio Pharma, Inc.的 52 周低点为 31.77 美元，52 周高点为 84.94 美元。</p>
</div><p>BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.14). The company had revenue of $194.52 million for the quarter, compared to analysts' expectations of $178.07 million. The business's revenue was up 66.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.88) EPS. On average, analysts forecast that BridgeBio Pharma, Inc. will post -2.27 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>BridgeBio Pharma（NASDAQ:BBIO - 获取免费报告）最后一次公布财报是在 5 月 7 日，报告显示该季度每股收益（EPS）为-0.84 美元，低于分析师共识预期的-0.70 美元，差距为 0.14 美元。该季度的收入为 1.9452 亿美元，而分析师预期为 1.7807 亿美元。与去年同期相比，该公司的收入增长了 66.8%。在去年同期，该公司每股收益为-0.88 美元。分析师平均预测 BridgeBio Pharma, Inc.在当前财年将发布-2.27 的每股收益。</p>
</div><h2>Insider Buying and Selling at BridgeBio Pharma</h2>
<div class="lb-trans"><h2>BridgeBio Pharma 的内部买卖</h2>
</div><p>In other news, Director Randal W. Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $75.46, for a total value of $754,600.00. Following the completion of the sale, the director owned 11,589 shares of the company's stock, valued at $874,505.94. The trade was a 46.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CEO Neil Kumar sold 40,000 shares of BridgeBio Pharma stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $67.90, for a total value of $2,716,000.00. Following the completion of the sale, the chief executive officer directly owned 575,686 shares of the company's stock, valued at approximately $39,089,079.40. This represents a 6.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 239,084 shares of company stock valued at $16,615,979. 14.23% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Randal W. Scott 在 2 月 17 日的交易中出售了 10,000 股 BridgeBio Pharma 的股票。该股票以平均 75.46 美元的价格出售，总价值为 754,600.00 美元。出售完成后，该董事持有 11,589 股该公司的股票，价值 874,505.94 美元。此次交易使其持股减少了 46.32%。该出售在向证券交易委员会提交的文件中披露，相关文件可在 SEC 网站上获取。此外，首席执行官 Neil Kumar 在 5 月 7 日的交易中出售了 40,000 股 BridgeBio Pharma 的股票。该股票以平均 67.90 美元的价格出售，总价值为 2,716,000.00 美元。出售完成后，首席执行官直接持有 575,686 股该公司的股票，价值约 39,089,079.40 美元。这代表其持股减少了 6.50%。该出售的披露信息可在 SEC 文件中找到。此次交易是在预先安排的 10b5-1 交易计划下执行的。在过去的 90 天内，内部人士已出售 239,084 股公司股票，价值 16,615,979 美元。当前 14.23% 的股票由内部人士持有。</p>
</div><h2>BridgeBio Pharma Company Profile</h2>
<div class="lb-trans"><h2>BridgeBio Pharma 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.</p>
<div class="lb-trans"><p>BridgeBio Pharma, Inc 是一家临床阶段的生物制药公司，总部位于加利福尼亚州帕洛阿尔托。该公司由 Neil Kumar 于 2015 年创立，致力于为患有遗传疾病和癌症的患者发现、开发和提供变革性药物。BridgeBio 采用一个综合模型，涵盖靶点识别、临床前研究、临床开发和商业化，旨在简化从实验室到临床的过程。</p>
</div><p>BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.</p>
<div class="lb-trans"><p>BridgeBio 的产品线包括多种治疗方式，包括小分子、生物制剂和基因疗法。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than BridgeBio Pharma</li>
<li>MarketBeat Week in Review – 05/11 - 05/15</li>
<li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li>
<li>Datavalut Gains Traction: 5 Reasons to Sell Now</li>
<li>TMC Stock: Why This Pre-Revenue Miner Is Worth Watching</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 BridgeBio Pharma</li>
<li>MarketBeat 周报 – 05/11 - 05/15</li>
<li>Viking 股价创历史新高——基本面信号显示未来还有更多</li>
<li>Datavalut 获得关注：现在卖出的五个理由</li>
<li>TMC 股票：为什么这家尚未盈利的矿业公司值得关注</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkJJTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=BBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in BridgeBio Pharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 BridgeBio Pharma 吗？</h2>
</div><p>Before you consider BridgeBio Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 BridgeBio Pharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 BridgeBio Pharma 并不在名单上。</p>
</div><p>While BridgeBio Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 BridgeBio Pharma 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

VIRGINIA RETIREMENT SYSTEMS ET Al Increases Stock Holdings in BridgeBio Pharma, Inc. $BBIO

Market Beat

Bridgebio Pharma

标普全球医疗股指数 ETF - iShares

美国制药 ETF - iShares

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

第一地平线

Huntington Bancshares

Truist Financial

加拿大皇家银行

富国银行

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

弗吉尼亚退休系统等机构增加了 BridgeBio Pharma, Inc. $BBIO 的股票持有量